Johnson & Johnson (JNJ) financial statements and ratios from SEC XBRL: revenue $94.19B (TTM), net margin 28.5%, revenue growth 6.6% YoY, P/E 30.7. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $94.19B |
| Net Margin | 28.5% |
| Revenue Growth (YoY) | 6.6% |
| EPS Growth (YoY) | 0.0% |
| FCF Growth (YoY) | 157.3% |
| P/E Ratio | 30.7 |
| EV / EBITDA | 20.5 |
| Price / Book | 7.60 |
| Price / Sales | 6.60 |
| FCF Yield | 3.4% |
| DCF Value (model) | $148.39 |
| DCF Upside vs Price | -44.6% |
| Altman Z-Score | 5.50 (safe) |
| Piotroski F-Score | 3/9 |
| Sector P/E (Healthcare) | 21.6 |
JNJ overview · JNJ earnings · JNJ KPIs · JNJ investor relations · JNJ ownership · JNJ peers · JNJ filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.